Q3 2019 Earnings Call
Gentlemen think a pretty stunning and welcome to at least steel and pharma results for the third quarter up 29 in conference call.
All participants are in listen only mode. After the speaker presentation W. Baird <unk> answer session to US a question. During this session you will lead to press star and what are your telephone.
But should that this conference just because of course it today Thursday, 14th often November 2019, and I would like political conference, but to your first speaker today misled name or fun. Please go ahead.
Thank you and welcome to dealing Pharmas conference call for the third quarter fiscal year 2019.
Leading today's call our Zealand CEO and many lots of luck.
C S O <unk>, Dallas and Chief Medical in Development Officer Adams seems Burke.
Then you I will provide business highlights from the third quarter in period thereafter, Matt will add financial highlights in animals follow with updates from our research and development programs.
After the prepared remarks, we will open the call to take your questions.
Joining to the Q unable to even <unk> senior Vice President technical development and operations.
Well, we know Garcia's senior Vice President corporate and business development, and Reshapes Hanson, Vice President of research and interim Chief Scientific Officer.
You can find the company announcement containing the Q3 interim reports and additional supporting information in the Investor section of our website at sea lymphoma Dot com.
As a company headquartered in Denmark or financials are reported in Danish crown's referred to as Cronin.
Key figures me just been converted to U.S. dollars for convenience.
On page one.
Well not that we will be making forward looking statements that are subject to risks and uncertainties.
These statements are valid only as of today and the company assumes no obligation to update them, except as required by law.
Please refer to recent filings for a more complete picture of risks and other factors.
And with page two I will turn the call over to many well.
Thank you ladies.
Thanks to everyone for joining the call today.
Didn't formats made impressive progress so far this year.
We already Fido strategy and advance our pipeline.
Or existing partnerships where strength.
New partnerships, where secure financial strength was reinforced with up before from a significant private placement we have an existing shareholder.
Yes, <unk> piece of our company is driven by a highly committed employees.
And we have but it's fair to tell them to the teams supporting both our recent achievements and long term value creation.
If you turn to page three.
You can see how all of these achievements are part of the exciting journey that even if they can we that's opportunities to improve patient lives, but providing leading that such properties.
We have one of the most productive unpromising platforms and bad thing that's been built over the last 20 years.
Oh peptides European platform and know how.
I've been repeatedly validated by partnerships with industry leaders.
To put keep results demonstrated knowledge peoples.
Yes.
In 2019, we have taken big steps to what our ambition to become a food integrate basic middle school and commercial operations.
We are rapidly preparing to take a home products registration and commercialization.
For exciting launches planned in the next four years.
The first and speed it to stop in 2020 warm.
Moving ahead to pitch for.
You will see business highlights for Q3 and into period after.
We were thrilled with the results from the pediatric studies the phase three Pico for ones, what does it get going to treat I feel good senior.
It was it wouldn't you built on which we completed the clinical program and through <unk>.
To suddenly early next year.
The potential of does if you're getting continues to grow phase two proof of concept trial was initiated to explore does if you're getting these potential to treat patients experiencing thatll be cynic events following.
During surgery.
The study what further I mean, the potential of me do but did you get.
And then we'll go into further details on these programs later in the cool.
You know when completed its first ever acquisition, we've been cycle tropical.
This is fortunate she was first rate by our research team.
We were eager to bring in the lead fit strategically expanding pipeline, we've announced before but it's seven integrated theater with potential for oral delivery.
We strengthened financial position with a significant private placements from bundrick investments.
They have been a long time investors.
And the additional 560 million corner investment showed their continued support and validation of our company.
Finally.
Has been warm school to had on your CFO , Matt That's on board since October .
That's very experienced.
Isn't biotechs yet.
You didn't into Boston area, where we are said machine or U.S. operations.
Welcome him to his first quarterly call with us.
And we'll hear from that in just a moment.
All of these accomplishments were made wide relocating to a new headquarters.
New home maintains the strong zemin culture.
And building, both our current transformation and future potential.
We can see actual transformation as the construction work to install all laboratories continues.
Inside the walls. There is this it was it to use people didn't stop the head.
Such pitch five summarized the acquisition of in cycle.
And the lead us it into a piece for us.
This was the first acquisition in the company's history.
The newly named <unk> 10000.
Our outside for better integrate into either represents a strategic expansion of our pipeline in gets it gets to into chemo disease and introduces new potential for oral.
Into appetite.
We appreciate that entities like and cycle recognize zealand's expertise and capabilities that quite research and development.
Finally, the financials ERM acquisition in a de risking investment approach.
Lois to sustain up its I phone, while continuing to build expertise and add new potential into our preclinical pipeline.
On page six.
We consider approach to commercialization the do it.
Looking at the you're ahead, we can pinpoint several did variables that are important for launch readiness.
The next year, we will open the facility in Boston.
Most of these ahead for biotech innovation.
We have been recruiting in this area already to feel the top leadership positions for U.S. organization.
Drawing on the deep dive into already available there.
Current partners Onyx, John and bits of Oneq I quoted in the Boston area.
And we see opportunity to leverage being neighbors.
And the multitude of biotech and pharma companies in Massachusetts.
Also in early 2020.
We remain on track to find the and you hold it does he can get hypothalamus Japan.
We accelerated many activities this year to build up our U.S. presence to launch that's like always keep than.
But it is important to realize that we our founding the team who will launch three other potential treatments soon after the risk. It then.
Then as an ambitious plan during the next four years.
And we're well on our way to ensuring successful operations, you know largest commercial market.
Advancing to pitch seven.
I will turn the call over to CFO , Matt asked to review financial results throughout the quarter quarter welcome that.
Thanks, Matt well.
Through the first nine months in 2019, Zune reported net operating expenses of 431.5 million.
Net operating result was a loss of 402.1 million shown on the left at the slide is when adjusted to reflect the guidance on that operating expenses, which remains in line with our ambitions <unk> fully on programs to the market. We remain on track the full year net operating expense guidance of 582 600 million.
On the right of slide you can see that our cash position remains strong cash and securities.
1.5 billion kroner 225 million U.S. dollars. This includes funding from the Ben Hur private placement completed in September .
Page nine I will turn the call over to items discussed Phillips from R&D.
Thanks, Matt.
So on page 10, you'll see the overview of sealants who'd bust pipeline.
Today, I will provide updates from the clinical programs and the programs partner with the ingelheim.
Also I think it's very good to note the early pipeline accretion of the out before because seven integrase inhibitor, which Emmanuel I discussed earlier.
On page 11, I will review.
Our clinical program targeting short bowel syndrome.
So you have to type that is our long acting to be two analog potential to weekly administration in an ultimate objective.
We expect to have approximately 50 patients randomized in this study it this year and compete enrollment next year next year.
The lease insight indications in U.S., and UK has cost and lower than expected patient enrollment in 2019, however over the last quarter. Our team has worked diligently to overcome these tenants is that's a good momentum on the newly activated centers and based on these activities. We now have 32 sites.
Activated and the majority of sites enrolling that those patients.
That's all those results from this study will be pushed into the first top 2021, we remain confident towards keeping our target for India submission.
Thank you 21.
On 750, 75, Siminski, we're seeing very good clinical progress based on the upsets safety and Tolerability of to single ascending phase. One trial was initiated in June this year, we're happy to announce that we now plan to initiate the phase one E multiple ascending dose.
Safety and Tolerability trial early next year.
50, 70, 576 unique dual acting.
One to equities, which we believe represent the next level of innovation in treatment of short bowel syndrome.
Moving to page 12.
I would like to turn your attention to the hydropower rescue pin for treatment of severe hypoglycemia in diabetes.
Last quarter, we reported the results from the pediatric phase three trial and DAP I couldn't even if its food based fee program for the hydropower rescue and.
This study utilized to St. Those as administer two adults.
And the pediatric study confirms the median time to test mclucas recovery from hypoglycemia up only 10 minutes from injection, which was also seen across the adult trials.
We believe the time to rescue it's going to be an important factor of patients and caregivers when considering rescued solutions for treatment of severe hypoglycemia and we're looking forward sharing more results from our program at upcoming scientific conferences.
With the clinical program conclude we remain on track for submitting the new drug application to the FDA really 2020 .
Turning to page 13.
You can see that we officially multiple opportunities with basically look on the on the hydro codrescu pin.
Great and buy on patients since forming management of type one diabetes and should we choose the burden of living that this serious condition. We have wasn't with visa bionics to develop that you can look on for use in the I did buy on five or more bionic pancreas.
We believe that the results from the Phase two study announced in Q2. This year demonstrated unprecedented glycaemic control by the bias on long island compared to an insulin only setting.
And together with Pizza Bionics, we're working closely with FDA two planned pivotal phase three trial that is set to begin late next year.
Our third basically work on program aims to change the life for children and families living with congenital hyperinsulinism.
First phase fee study with children, aged three months to 12 years.
Hootman continues to make strong progress with 16 patients now randomized to the end of October and results from this study is expected in 2020 .
Second phase three trial will enroll 12, CSR children from Newport up to one year and it's still plan to stop in this quarter.
Finally in October this year and new clinical program was initiated for that's it we're going to evaluate its potential as a novel treatment for patients.
Mostly I think surgery hypoglycemia, and we expect we saw some this phase two clinical proof of concept dose finding trial in 2020 .
On page 14.
But we provide more details on the opportunity for data you can work on me dosing to patients suffering from weakens hypoglycemic events that are difficult to managed by carbohydrate ingestion.
And number of patients who have undergone by adding surgery as a treatment for obesity experienced reacted hypoglycemia asset eating a meal.
Yes.
Shifting additional food, bringing to increase passionate glucose is not an option.
No approved treatment option for these estimated 6000 patients in the U.S., who suffers from this year's condition and we believe that that's it look on multiple dose pin may provide an attractive treatment option.
We also believe that basically like a need doses may provide an attractive treatments solution for people with type, one diabetes, who experiences hypoglycemic events and for whom eating and drinking carbohydrates, it's not an option similar to the post by adding patients.
So our team is shustek about these potential usages of basically look on and we look forward to the results from the phase two study next year and to continue its exploring this as a full treatment modality for basically work on.
Moving to page 15.
No R&D program updates for this quarter I would our popping up in the ingelheim.
For the GLP one cubic on equities, we announced earlier Q3 that doing that decided to advance this target to face to face and positive outcome in phase one.
The phase two trial is expected to enroll the first patients this quarter.
And we'll be a 16 week randomized parallel group those finding trial in 410 patients with type two diabetes.
The primary comparison will be to proceed.
And Semaglutide will be included as an exit comparison.
The main objective of the study is to explore exited changes in H. gave on C. and secondary assessments include changes in body weight.
On the M&A in program, we expect update something early next year, and thus moving phase one he chasing into 2020 .
Going to page 16, I will now turn the culturally manual for his concluding.
Comments.
Thank you Adam.
Andy Thanks to the research and development teams for the outstanding progress today and congratulations on all of the positive results demonstrated throughout the studies.
Page 17.
Shows the major milestones that Didnt pharma has accomplished in 2019.
We have advanced all of our late stage clinical programs and seen posted results from two of them so far.
We advanced our Prequaled program into phase, one and certain method or early pipeline with the confidence first acquisition.
Our existing Quadracci this one's with Boehringer ingelheim and bits of earnings midpoint progress.
But you did talk perspective in peptides and developing innovative therapeutics, we formed a new exciting partnership with industry leader addiction, and most recently secured significant funding from existing shareholder been hit investments.
So 2019 has been a remarkable year for dinner.
We are moving faster than ever one mentioning integrity in operations and clinical activities.
In 2020 .
We look forward to submitting to rescue Pan India. In addition to delivering on optical programs as we continue to create value for shareholders by developing innovative peptide treatments.
Thank you menu well this concludes our prepared remarks and thank you for your attention thus far.
Carl we're now ready to take questions. If you. Please open the lines.
Okay, Ladies and gentlemen, who will now begin to question answer session and as a reminder, if you wish that that's a question. Please press star in one your telephone.
He needs to be in that one.
And my fellow take our first question and her first question comes from the line off David Lebowitz. Your line is helping.
Thank you very much for taking my question, what do you feel to compare the actual it patient experience of administering the IPO Penn versus the experience of administering.
Oh, there rescue pens and that are out in the market.
Yes.
That will take this question. Thank you David. Thank you David Thanks for the question I think it's of course, a highly relevant Christian but actually will also noticed our clinical program have used the old to work on kids as comparisons.
Which are the products are reconstitution, we have not done direct comparisons to the current be approved recently approved the ready to use solutions.
The only thing we can share is of course the outcome of market research that we have conducted with suggested both prescribers and patients pursue an injectable Oh, oh nasal but I mean these these on market research data. So we have no direct comparisons.
Things from patients it.
However, I mean now phase three are available for all these products and so I think you can look at Sno indirectly compare these studies and results, but they just just a cushion they use actually somewhat different endpoints.
But there are some interesting.
Findings that's no shows a difference again, there hasn't been you know choices for patients in the past so I think the the advantage.
Now that's you know patients without the choice between several products. So there will be actually a more scrutiny key differences among products. We believe we have actually a very good.
Thats actually for patients.
Thank you for that and it's the pen that's used with that as a gun.
Similar to the pen that will ultimately be use for go paclitaxel.
And if they are similar but they're not same.
I guess, how likely ethnic be different concepts that so both those have caused subcutaneous injections, but the rescue Penn has been designed to serve a rescue emergency need and the end used for that for you if egrets side.
It's designed for chronic use so I mean, it I'm sorry, if I repeat.
Using an acute setting so similar concepts auto injectors both of them subcutaneous.
At the same.
Thank you for taking my questions.
Computers.
Okay. Our next question comes from the line of Petsmart Darla. Your line is how open.
Great. Thanks for taking my question just a couple from me as far as sort of the delays.
And the eat you listen in the UK for the site activation I wondered if you could speak to maybe some of those specifics and whether or not they've been fully resolved and and I guess secondary to that and the glip ugly tied as zippy 70, 570, I guess given the timeline expectation could we see results for for both of these.
Studies in the first half of 2021, and then I'll have a follow up question.
Okay. Maybe on your first question I've I think I I can heavily say that would help resolve the issues with the UK and U.S. size and there were a little bit if a different issues in U.S. I mean, it's known that it takes time to open science and U.S. due to contract negotiations and so and so forth.
So that we have made some changes in the in the people working on the trial and then that we have very very positive feedback with from a zero side.
And in UK, what's actually in extrinsic factor.
Due to some quality issues with the parental support.
That that patients were giving at decided that we.
Our next Gen provider.
Supporting the clinical sites with parental support they had some credit quality issues sites has had to change providers and of course that created some logistics issues for these sites that has also been overcome by the sites now. So they are now back in you can say normal operations and can focus on our clinical study.
So in that sense, we are actually.
Very happy with the development, we have seen I was saying the last few months.
In the study and decide activation. The last question could you just repeat that the last how does your question.
I guess given given so the expectation on the good peddler time results now and 2021 could we also see zippy 70 570 of phase wouldn't be results in that same sort of timeframe.
The the.
Yes.
Yeah for Seppi 70, 570, we will we expect to have that results in 2020 I would say of both the single ascending dose and the multiple ascending dose trial.
Thank you.
It will be coming up next year.
That's great and I guess, the because of the other question is going back to sort of the severe hypoglycemia market is it too early in terms of see what and Pat I'm sort of the for competitive agent. The Bugs me product has had sort of oh not market or do you think that some.
In that would take a little bit more trying to kind of start seeing.
No. There are some actually publicly available data a that I've shown very very good response to promotion in the market. So again, it's markets as hasn't been actively promoted for the last 15 years and the launch of vaccine has actually injected some much wanted.
Actually energy and dynamic in the a in the market so over the last 10 weeks.
Globally in the market has expanded by 20%.
And 17% of this 20% on new patients you prescribe patients.
So it's a very positive dynamic and again these markets is expected to doubled or tripled in the next three to five years and I think it's taking the the right direction right now.
Great. Thank you for.
Theres no there hasn't been any product differentiation in the past. So think vaccine is actually in the first new innovation. This market. We believe that one dimension, which is very important for patients or when they will have the choice will be the speed at which they can manage their company. These events I probably speak to that.
So I think this is a very important I mentioned for us.
What we saw.
Great. Thank you and congrats on all the progress.
Thank you. Thank you very much for your questions.
Okay. Next question comes from the line of Alan Carr. Your line is how open.
Hi, This is Jerry on for Alan Thanks, a lot for taking my questions a few more on the clinical inside sort of enrollment.
Could you.
Provide us with with a you know you mentioned.
Like the patience.
By the end of this year, but how many.
Our enrolled as of as of now and have you seen since you sort of resolve these issues with the.
With the external.
With the external hires have you seen is it too early to see an uptick sort of in the enrollment from from that and just.
Just a just to be clear is.
Was there any higher than expected screening failure rates or has that changed over time.
I know that's a separate issue maybe than me.
Then the parental support but maybe if you could.
That's a more.
Color on that that'd be great.
Right. Okay. Thanks for the question I can provide a little bit more.
Carlos <unk>, if I should just talk about the screen failure then decide.
For the year on the first half, we did see a little bit higher screen failures and anticipated, but again. This is a nice thing that we can learn and educate the sites and investigators. So so we see a reduction in that so that that is has clearly got into positive direction on the external factors that wasn't that was an issue that was really specifically related to UK.
It's a and that provide a parental support which has been solved so that that is not an issue on the you can say the U.S. side. That's why we had some may make some changes also in the personal at the show and we have very positive feedback from the U.S. investigators on the people that then I'll collaborating with from us.
So that is also something you can see there so.
I should then.
In the number of patients we have tried right now.
My My belief is we are around just below 40 patients as we speak who have been randomized and we guide for 15.
And you can say the predictions now for for when we will have the patients enrolled as I also mentioned in the call. We have a 32 sites activated and within the next month or two we expect that number to be around 37 sites.
And then as you know, it's a 129 patients study, meaning that we will have to recruit another 80 patients. So that if you just look at the number of sites. It's actually something we can see individuals who we with the new guidance. We would have to have let's say 10 to 15 patients entering the study to months, which is in line.
What we are starting to see right now.
So that's why we have confidence in what we communicate yet.
Okay, great so more of a hockey stick type of enrollment.
Let me pick up additional sites.
And just a quick one on Desi, maybe just some high level.
Commentary around the commercial pricing.
No you're planning to fill that your commercial team and a 2020 and maybe what percent of the total commercial team have you hired thus far and you could just maybe a breakdown of how many you.
Plan on hiring.
In 2020, but before the launch thank you.
Yeah, George that's that's a that's an interesting questions, but that's a very competitively sensitive as well. So we will not communicate on the detailed information to the team and the number but I can tell you that you know the or what's the plan. We're following is very very.
Classic you mean, we are actually starting to higher by all the leaders of each functions and very quickly. Even though then after you know the leaders are actually bring onboard their direct reports and they actually the final in detail in the plan you know.
Two level. That's a detailed that's you know we haven't been able to implement yet so I would say what we have today is typical you know in operational is probably 80% correct and then as we go we actually still you know refining and we actually modified 80 or 90% of it as we go so.
This is this is typical and with up to the situation, where we are right now in terms of to gain of respond to use up responding, but we have line of older leaders of all the different assumptions and they are either on gold or we are about to actually on bought them.
Alright, thanks for taking my questions.
Okay. Next question comes from the line of flu C Corps Clarington your line is helping.
Hi, there. Thank you for taking my question and just a couple from me. The first question relates to the artificial pancreas and given where they already had some meetings with the FDA just wonder why the phase three is not going to start till they.
At the end of next year, and then if you could give us any idea on timing. So understanding the final plan has that they decided.
Secondly, and if he could that's now whether that this stuff that long acting amlin with it the I am collaboration will trigger a mile staying.
Then lastly.
Just on the data that's been disclosed to the hydropower risky pad and.
It's not been particularly teach outs I saw I just wanted to.
For coated median time to the treatment and success it and the competitive you mean time I just wonder if there's a reason for that thank Keith.
Okay, maybe I can take icon to these weve, Chris and see if I start with the last one so.
The way, we define our primary endpoint that protocol that was the median time and we also used to upset.
I mean, which mean its with media and it's actually the time, where we do the sampling. So it's a first time to have a 20 milligram could trend to potentially different could easily the increase investment because we could have used to meantime, and they have served and the true means.
Then we would have probably nine minutes instead of 10 minutes on average on these results. So it's I was thinking it would only went to our benefit to actually changed the way we would report outcomes, but the way we decided to studies and the way. We think is scientific he knows and clinically relevant.
It's how we are presenting the data, but I would say, but even without benefit if we use the other ways to report the data.
If you look out to the amylin collaboration there will not be a milestone associated with startup phase one, but there will be milestones wants that program is getting into phase two and we have outstanding milestones of.
283 million and as we also got mid to single to low double digit royalties on global sales.
So, but that will not get milestone with the mutation of phase one with that I mean.
On that.
On the dual home and artificial pancreas, you're right. We've reported the phase two data in Q2, and we are in a very positive dialogue with FDA because of the pizza bionics discussing the phase three program and hope soon to be able to to provide clear guidance to the market for this we are excited us as we have shed.
And see very good progress the reason that we do not believe we can start to started before late next year I think there several effects as one is it takes time to finalize the protocol. He had submitted and finally approved and then also gets contracts and decide up running that that typical takes some time and the other thing of causes that the you can see the truck.
I think look on has to be ready for phase three we believe we have a product that can go into phase three than the device also has to be ready to go into phase three so it's its getting all of these pieces together.
Which will take us into into late next year.
It's a bionics their communicated that they anticipate to start a study with the insulin only function first which we actually.
So so and then we will start to two homes with another piece of our earnings after that.
But oh rest assure that we are actually challenging these timelines all the time and what we are providing theory, it's actually a fairly aggressive fivenine phase on our capacity our knowledge of the market and the partnerships that we have to actually aligns with that.
But we are going as fast as we can.
Hey, thanks, so much.
Okay. Once again, if you wish the other question. Please press star in one.
Okay. Next question comes from the line up Peters said said your line is helping.
Yes, Peter I'm answering the second for taking my question.
Select too.
Often ask question of the pricing strategy for testicular gone because now you introduced it to a potential fourth indication.
You could argue that pricing could be higher than no for traditional rescue.
Mr indication in type one diabetes.
So just recap.
And that onto to what you said before.
The price increase.
So maybe you could I can just saying say one thing before I know it talks about a month and.
And one thing is if it's extremely important to notice that its four different product presentations were discussing here. One is a rescue pin intended for a single dose use when you have an emergency situation in all to inject them.
For the two at home and it's a cottage for that we did it up for two hormone system for chronic treatment.
Genital hyperinsulinism silliness, it's actually a chronic infusion. It's also a conscious being used for chronic infusion and then for the mini those concept in a pin it it is a repeat use doable 10.
So again at fourth product presentation. So that of course creates optionalities here and it's also very different doses of the drugs. You would you would use considering that they opened six milligram.
Those that you would use and then rescue setting for the chronic use it programs. It's it will be much more people about you would use over the course of the idea of course.
Yeah on top of that they would add that you know these are different markets as well so in the rescue market seasonable that the prices sets and there's a really like existing products and so I think you have to align with the with the markets already accessing a India. Other indications these are totally blue ocean. So there.
Next three indications, we would be first in class and so.
We are then looking at you know this formulations the a the dosing the different you know presentation of the products and it seems like you know on top of that we say, we add which we believe is actually a the company philosophy that we will price responsibly for all these indications. So so we're not there yet.
And we're still actually a working on these scenarios, but I can assure you that you know we are we are actually taking a very responsible approach to these pricing.
Today, I mean, there's a lot of synergies there around that and ER and we we are make we will make sure that we will provide.
Very good value for for the for the products we price.
I was just follow up question true to the jewel.
[noise] agonist product.
Should we expect to see any type of fees one thing to Oh I should we just told on until we see the phase two and Furthermore, this phase two study.
The potential stepping stone for phase three.
Or should we see a fees to be study being.
Being started with a.
Uh huh.
Hey, once she and her weight outcomes prime in before points before you move into phase three thank you.
Yes, I mean, we it will be up to if they're not too. So of course decide when to pop is data. So we cannot comment on it.
If you will see it'll be able to share phase one data.
Oh, we have the phase two data I think if you look at the phase two study that they're standing here, it's following that and 10 patients it's actually six different doses.
Of the product that are being tested and it's a 16 week study, which.
Should provide enough data to move into phase three but again it will ultimately be attributing it to make these decisions and we when we do with the this such a study or I should look at a study like this I would consider that study that would allow.
Let's move directly interface fee I for the outcome if it turns out positive thing.
Yes.
Thank you.
Thank you Peter.
Okay. Once again, please press Star then one if you wish to last question.
[noise].
Okay, Sir no further questions at this time discontinued.
I guess.
Thank you Sir no more questions. Then we will go ahead and conclude today's call. Thank you very much for joining in for your participation.
Okay. Thank you.
Thank you again.
Okay that does conclude or conference for today. Thank you for participating you may all disconnect.
[noise].